Announcement of Resolutions of the Ninth Meeting of the Fifth Board of Directors of Antu Biotechnology
Securities code: 603658 Securities abbreviation: Antu Biotechnology Announcement number: 2025-081
Zhengzhou Antu Bioengineering Co., Ltd.
Announcement of Resolutions of the Ninth Meeting of the Fifth Board of Directors
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
All directors attended this board meeting.
No director voted against/abstained from voting on this board meeting.
All resolutions passed by the board of directors were approved.
1. Convening of board of directors meetings
The meeting notice and materials for the ninth meeting of the fifth board of directors of Zhengzhou Antu Bioengineering Co., Ltd. (hereinafter referred to as "Antu Bio" or the "Company") were issued by email on December 6, 2025, and the meeting was held on December 9, 2025. The company's conference room was held by a combination of on-site and communication methods. The meeting should be attended by 12 directors, and 12 directors actually participated in the voting (including director Mr. Zhang Yaxun and independent director Mr. Yuan Huagang attended the meeting by communication, and director Mr. Yang Zengli participated by proxy). The meeting was chaired by Mr. Miao Yongjun, chairman of the company, and some senior managers of the company attended the meeting.
The convening and holding procedures of the meeting comply with the relevant provisions of the Company Law and other relevant laws, administrative regulations, departmental rules, normative documents and the Articles of Association, and the resolutions formed at the meeting are legal and valid.
2. Review status of board of directors meeting
After careful deliberation by the directors present at the meeting, the following proposals were unanimously adopted by registered vote:
- Considered and approved the "Proposal on Using Idle Raised Funds for Cash Management"
For details, please refer to the announcement disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on the same day.
The sponsor agency China Merchants Securities Co., Ltd. issued verification opinions on this. For details, please see "China Merchants Securities Verification Opinions on Antu Biotech's Use of Idle Raised Funds for Cash Management."
Voting results: 12 votes in favor, 0 votes against, 0 abstentions.
- Considered and approved the "Proposal on Using Idle Own Funds for Cash Management"
For details, please refer to the announcement disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on the same day. Voting results: 12 votes in favor, 0 votes against, 0 abstentions.
3. Online announcement attachments
"China Merchants Securities' Verification Opinions on Antu Biotech's Use of Idle Raised Funds for Cash Management".
Announcement is hereby made.
Board of Directors of Zhengzhou Antu Bioengineering Co., Ltd.
December 9, 2025